Aczone Generic Approval In Sight, All Clear At Sites Key To Torrent’s US Outlook
Molnupiravir Launched In India
Executive Summary
Torrent expects US FDA’s final approval for Allergan/Almirall’s Aczone, a dapsone formulation for acne vulgaris, in February, even as it awaits regulatory clearance for manufacturing sites. Meanwhile, it has launched molnupiravir in India and is hiking its domestic sales force by 400-500.
You may also be interested in...
Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India
Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.
Torrent Acquires Chronic Brands From Dr. Reddy’s, Folds Up US Liquids Business
Torrent is recalibrating strategy with the addition of chronic therapies from Dr. Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.
Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals
More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron.